1 week Ago By Defense World Staff
Corebridge Financial Inc. decreased its stake in shares of ArriVent BioPharma, Inc. ( NASDAQ:AVBP – Free Report ) by 7.
0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,007 shares of the company’s stock after selling 1,057 shares during the quarter. Corebridge Financial Inc.
’s holdings in ArriVent BioPharma were worth $373,000 at the end of the most recent quarter. A number of other large investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co.
Ltd. bought a new position in ArriVent BioPharma during the fourth quarter worth $31,000. KLP Kapitalforvaltning AS bought a new stake in ArriVent BioPharma during the fourth quarter worth about $83,000.
China Universal Asset Management Co. Ltd. bought a new stake in shares of ArriVent BioPharma during the 4th quarter worth approximately $190,000.
New York State Common Retirement Fund boosted its holdings in shares of ArriVent BioPharma by 34.6% in the 4th quarter. New York State Common Retirement Fund now owns 7,783 shares of the company’s stock valued at $207,000 after purchasing an additional 2,000 shares in the last quarter.
Finally, The Manufacturers Life Insurance Company bought a new position in shares of ArriVent BioPharma in the third quarter worth about $240,000. Institutional investors and hedge funds own 9.48% of the company’s stock.
Wall Street Analysts Forecast Growth AVBP has been the topic of a number of recent research reports. B. Riley initiated coverage on ArriVent BioPharma in a research note on Thursday, March 20th.
They set a “buy” rating and a $37.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $39.
00 price objective on shares of ArriVent BioPharma in a research report on Friday, March 7th. Finally, Guggenheim initiated coverage on ArriVent BioPharma in a research report on Monday, March 10th. They issued a “buy” rating and a $45.
00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $39.
00. ArriVent BioPharma Stock Performance ArriVent BioPharma stock opened at $17.56 on Thursday.
The stock has a market cap of $597.32 million, a PE ratio of -6.83 and a beta of 1.
66. ArriVent BioPharma, Inc. has a fifty-two week low of $14.
35 and a fifty-two week high of $36.37. The firm’s 50-day simple moving average is $22.
29 and its 200 day simple moving average is $25.95. ArriVent BioPharma ( NASDAQ:AVBP – Get Free Report ) last released its earnings results on Monday, March 3rd.
The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.
18. As a group, analysts predict that ArriVent BioPharma, Inc. will post -2.
74 EPS for the current fiscal year. ArriVent BioPharma Profile ( Free Report ) ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
See Also Five stocks we like better than ArriVent BioPharma Using the MarketBeat Stock Split Calculator Quantum Computing: The $6.5 Billion Opportunity You Can’t Ignore Manufacturing Stocks Investing Are Tariffs Threatening Disney’s Comeback Story? How to Know if a Stock Pays Dividends and When They Are Paid Out Is Alphabet a Generational Buying Opportunity at These Levels? Want to see what other hedge funds are holding AVBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ArriVent BioPharma, Inc.
( NASDAQ:AVBP – Free Report ). Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
